Loxo Oncology

Voyager clears Neurocrine agreement for Parkinson's gene therapy Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech USD 165 million upfront. In return, Neurocrine benefits certain rights to four gene therapy progra...

Apollomics raises USD 100 Million for funding of transpacific cancer R&D plan Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apo...